Home
>
National Drug Code (NDC)
>
VARIZIG
VARIZIG - 53270-0125-2 - (Varicella Zoster Immune Globulin (Human))
Drug Information of VARIZIG
| Product NDC: | 53270-0125 |
| Proprietary Name: | VARIZIG |
| Non Proprietary Name: | Varicella Zoster Immune Globulin (Human) |
| Active Ingredient(s): | & nbsp; Varicella Zoster Immune Globulin (Human) |
| Administration Route(s): | |
| Dosage Form(s): | KIT |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of VARIZIG
| Product NDC: | 53270-0125 |
| Labeler Name: | Cangene BioPharma |
| Product Type: | PLASMA DERIVATIVE |
| FDA Application Number: | BLA125430 |
| Marketing Category: | BLA |
| Start Marketing Date: | 20130226 |
Package Information of VARIZIG
| Package NDC: | 53270-0125-2 |
| Package Description: | 1 KIT in 1 CARTON (53270-0125-2) * 1 mL in 1 VIAL, GLASS * 8.5 mL in 1 VIAL, GLASS (53270-0177-1) |
NDC Information of VARIZIG
| NDC Code | 53270-0125-2 |
| Proprietary Name | VARIZIG |
| Package Description | 1 KIT in 1 CARTON (53270-0125-2) * 1 mL in 1 VIAL, GLASS * 8.5 mL in 1 VIAL, GLASS (53270-0177-1) |
| Product NDC | 53270-0125 |
| Product Type Name | PLASMA DERIVATIVE |
| Non Proprietary Name | Varicella Zoster Immune Globulin (Human) |
| Dosage Form Name | KIT |
| Route Name | |
| Start Marketing Date | 20130226 |
| Marketing Category Name | BLA |
| Labeler Name | Cangene BioPharma |
| Substance Name | |
| Strength Number | |
| Strength Unit | |
| Pharmaceutical Classes |
